| BACKGROUND
The European Medicines Agency (EMA) has the responsibility for the scientific evaluation, supervision, and safety monitoring of medicines in the European Union (EU) to ensure that their benefits outweigh their risks. While the roots of medicines' safety monitoring lie in the development of mechanisms for spontaneous reporting of suspected adverse reactions by health-care professionals and patients, the importance of using the full spectrum of evidence including observational studies has long been acknowledged. [1] [2] [3] The risk management system introduced in the EU in 2006 highlighted the need to build capacity and to facilitate the conduct of multicenter independent postauthorization studies to investigate important risks or missing information in European populations. 4 In 
2008
. 6 Ten years on, we review ENCePP's main achievements, discuss its impact on the benefit-risk evaluation of medicinal products in Europe, and outline future perspectives.
| WHY WAS ENCEPP NEEDED?
Although collaborations for multicenter studies have long existed, the pharmacoepidemiology landscape in Europe has been heterogeneous and based on researchers using stand-alone data sources with limited sample sizes and applying differing quality standards. This heterogeneity was compounded by differences between health-care systems, uncertainty about available databases, and uncertainty on existing collaborations with sufficient expertise and capacity to conduct multicenter observational studies. It was often considered easier for industry to conduct postauthorization studies requested by EU regulators in the United States, despite differences in characteristics of study populations, clinical practice, and prescription patterns.
There was a need to foster a network of researchers able to perform
large observational studies in Europe and for a pool of experts providing clear guidance on best practices in pharmacoepidemiology.
At the same time, rules and principles for quality standards and transparency of research were also needed to ensure that these studies would be performed according to the best possible level of scientific quality. 5 Initiative. 9 In addition, ENCePP members provided occasionally to EMA data that could support drug safety reviews. This information covered topics such as combined hormonal contraceptive and the risk of venous thromboembolism, strontium ranelate in the treatment of osteoporosis, bromocriptine-containing medicines indicated in the suppression of lactation postpartum, ambroxol-and bromhexine-containing medicines and allergic reactions, codeine-containing medicines and the risk of morphine toxicity, or hydroxyzine-containing medicines and pro-arrhythmogenic potential.
The long-term success of the network will depend on its capacity to keep current members engaged and involve new members to take-up future methodological challenges, taking into account that new data sources such as social media and big data will likely play an increasing role in the benefit-risk evaluation of medicinal products. In this regard, a concept paper on methodological aspects associated with use of different models for data extraction and analysis from electronic health records, their validation, and their regulatory applications is being developed.
| Better knowledge and accessibility of data sources
An objective of ENCePP is to identify data from clinical or administrative electronic databases available in Europe, coordinate these data in a comprehensive and public inventory, and facilitate their access to researchers. Database holders and professionals with expertise in use of specific data sources are invited to provide a description of their core data (eg, coding systems and dictionaries used, type of events, and medicinal products covered), demographic information, information on data linkage and data access, and a list of relevant publications derived from the data. 8 Since 2017, disease registries are also registered in the context of the EMA Patient Registry Initiative. 10 As of July 31, 2017, the inventory included 83 data sources ( Figure 1 ). The inventory provides key information on a large number of databases and helps investigators identify relevant data sources available to answer specific research questions. It represents a core source of information on data available for the benefit-risk evaluation of medicines. Registration of studies in the EU PAS Register has changed the landscape of pharmacoepidemiology and pharmacovigilance by giving 
| Better governance for studies including management of interests
In line with its aim to promote transparency and scientific independence, the ENCePP developed a Code of Conduct laying out best practice in the relationship between investigators and study funders, irrespective of whether the study funder is a public body, industry, or a regulatory authority. 22 At the core of scientific independence is the provision that no person with a financial, commercial, or personal interest in a particular outcome of the study shall take part in any study activity that could influence the results or their interpretation in any particular direction. To ensure transparent research, the code requires registration of the study in a public registry (for instance, the EU PAS Register) and agreement to make public relevant Table 3 
| FUTURE PERSPECTIVES

